JPRN-UMIN000009773已完成未知
Clinical usefulness of serum HER2 in gastric cancer (Serum Her2/neu elevation in gastric cancer; A Multicenter trial in Hokkaido) - SHERLOCK 1 Trial
First Department of Internal Medicine, Sapporo Medical University0 个研究点目标入组 300 人开始时间: 2013年1月13日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Other malignancies within the last 2 years, except for carcinoma in situ or basal cell carcinoma. 2)Patients who are considered to be ineligible by referring physician.
研究者
相似试验
Unknown
不适用
The Clinical Study of Assessing HER-2 Expression in Gastric Cancer With Extra Tumor Tissue Paraffin Blocks Using ImmunohistochemistryGastric Cancer Surgical Specimens,18-80 Years Old, at Least Two Tumor Tissue BlocksNCT02843412Shanghai Zhongshan Hospital2,000
Unknown
不适用
Assessing Her2/Neu Expression in Gastric Cancer With Dual or Multiple Tumor Tissue Paraffin BlocksHER-2Gastric CancerNCT02852096Shanghai Zhongshan Hospital600
撤回
2 期
Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/OverexpressionRecurrent/Advanced Gastric CancerNCT05512182Yonsei University
已完成
2 期
PF-00299804 Monotherapy in Patients With HER-2 Positive Advance Gastric CancerAdvanced Gastric CancerHER2NCT01152853Seoul National University Hospital28
Unknown
不适用
Evaluation of HER2-targeted Therapy for Gastric Cancer and Establishment and Verification of Monitoring SystemHER2 Positive Gastric CancerNCT05165602Peking University30